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Inrecent years severaltechnologies forthe complete analysisofthetranscriptome andproteome havereached a technologicallevel
which allows their routine application as scientiﬁc tools. The principle of these methods is the identiﬁcation and quantiﬁcation of
up to ten thousands of RNA and proteins species in a tissue, in contrast to the sequential analysis of conventional methods such
as PCR and Western blotting. Due to their technical progress transcriptome and proteome analyses are becoming increasingly
relevant in all ﬁelds of biological research. They are mainly used for the explorative identiﬁcation of disease associated complex
gene expression patterns and thereby set the stage for hypothesis-driven studies. This review gives an overview on the methods
currently available for transcriptome analysis,that is, microarrays, Ref-Seq, quantitative PCR arrays and discusses their potentials
andlimitations.Second,themostpowerfulcurrentapproaches toproteomeanalysisareintroduced, thatis,2D-gelelectrophoresis,
shotgun proteomics, MudPIT and the diverse technological concepts are reviewed. Finally, experimental strategies for biomarker
discovery, experimental settings for the identiﬁcation of prognostic gene sets and explorative versus hypothesis driven approaches
for the elucidation of diseases associated genes and molecular pathways are described and their potential for studies in veterinary
research is highlighted.
1.Background
The molecular aetiology and mechanisms of the many neo-
plastic, inﬂammatory, and degenerative veterinary diseases
are largely unknown. This information deﬁcit is caused by
several constraining factors such as the lack of the complete
genomic information or the unavailability of molecular
tools, for instance, species-speciﬁc antibodies.
Due to this lack of a critical mass of knowledge on the
disease mechanisms in veterinary medicine, hypotheses on
the pathogenesisof veterinary diseases are often based on the
knowledge on homologous human diseases. This approach
doubtlessly helped to elucidate the aetiology of several vet-
erinary diseases, such as the impact of mutations in the c-kit
receptor for some canine mast cell tumours [1]. However, in
at least the same number of studies, this approach failed to
identify identical mechanism in human and animal diseases,
most probably due to interspecies diﬀerences or plainly be-
cause of the absence of comparable human diseases.
An alternative approach to develop and test hypotheses
is to study known cellular molecular mechanisms or genes
whose dysfunction may theoretically causethe clinicalsymp-
toms and morphologic lesions. This includes the analysis of
the mutational DNAstatus and the RNAand protein expres-
sion levelsof these speciﬁc genes to elucidatetheir role in the
disease. However, due to the redundancy of gene functions
and the complexity of molecular pathways, the chances are
rather low to identify “the” disease-associated genes or mo-
lecular pathways by this approach. Furthermore, it becomes
more and more evident that most diseases and notably the
carcinogenesis of veterinary tumours are only rarely caused
by a mutation in a single gene but are rather caused by dys-
function of a wider array of multiple genes [2].
In case the above-mentioned hypothesis-driven ap-
proaches fail, non-hypothesis-driven, explorative studies are
feasible alternatives. This approach, however, needs tech-
nologies which facilitate the concurrent analysis of a large2 The Scientiﬁc World Journal
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Transcriptome
Proteome
Traditional analytical tools
PCR = 1g e n ef r a g m e n t
RT-PCR = 1 RNA specimen
Western = 1 protein type blot
Transcriptomics/proteomics tools
Microarray = up to 30.000 gene fragments/
RNA specimen
Ref-Seq = complete genome/all RNA
specimen
Proteomics = majority of proteins
∼25.000 genes
∼x-times 25.000 RNA specimen
∼x-times 25.000 protein types
Figure 1:TraditionalanalyticaltoolsforquantiﬁcationofDNA, RNA, orproteins arerestricted to thesequential analysisofonebiomolecule
specimen ata time.Research based onthesetools is therefore strictly hypothesis driven. In contrast,transcriptomics toolspermit the parallel
quantiﬁcation of thousands of biomolecules and therefore allowing for explorative, non-hypothesis-driven studies.
scale of the genome, the transcriptome, or the proteome in
diseased versus nondiseased tissues (Figure 1).
The so-called “-omics” technologies, which made much
headway in the last ten years, enable such an approach to
answer hitherto inaccessible scientiﬁc questions. The tran-
scriptome [3] which constitutes the complete set of RNA
specimen within a tissue, and the proteome [4]t h ec o m p l e t e
set of proteins in a tissue, have been named in analogy
to the genome, the complete set of genes of an organism.
In addition to these three dominating ﬁelds, several other
groups of biochemical elements have been coined in analogy
to the genome, such as the metabolome [5] ,t h ec o m p l e t es e t
of metabolic intermediates, or the glycome [6], the complete
set of cellular sugars, free or in more complex molecules.
This review aims to summarize the current state of the
art of technologies in transcriptome and proteome research.
Furthermore, the strengths and weaknesses of the technolo-
gies will be described, and potential applications in veteri-
nary science will be depicted.
2.MethodsinTranscriptomics
The term transcriptome embraces all types of complemen-
tary RNA synthesized during transcription of the genome at
ag i v e nt i m ep o i n t[ 3]. Of these, microRNA (miRNA) and
messenger RNA (mRNA) momentarily are the RNA types
of greatest interest in transcriptome research. The mRNA
expression levels directly reﬂect the gene activity of a cell,
while diﬀerences in miRNA expression levels, a major post-
transcriptional regulator of gene activity, are thought to be
associated with several cellular functions and diseases
[7]. Three common methods for the multiplex detection
and quantiﬁcation of miRNA and mRNA at a large scale are
momentarily used: microarrays, deep sequencing (RNA-
Seq), and quantitative reverse transcription (RT) PCR arrays
(Table 1).
2.1. Microarrays. A microarray is a multiplex, high-through-
put screening method which uses a two-dimensional ar-
rangement of nucleotide probes on a glass slide or a thin sili-
con chip [8]. One array can contain tenthousands ofnucleo-
tide sequencesorhypothetically the completetranscriptome,
which is covalently bound to the chip’s surface or ﬁxed in
parallel rows in microﬂuidic channels [8, 9]. Depending on
the scientiﬁc questions asked, these nucleotide sequences
may represent short fragments (probes) with exon sequences
to analyse the presence and the quantity of speciﬁc mRNA
ormiRNAin expression proﬁling experiments. Alternatively,
genomic DNA sequences with allelic variants, known muta-
tions, or single nucleotide polymorphism (SNP) is spotted
on the chips to identify the mutational status of a tissue
in comparative genomic analysis or SNP assays [10]. Inde-
pendent from the spotted sequences, pairwise hybridization
of the given sequences on the chip with complementary
DNA or cDNA sequences (targets) in a tissue lysate under
high-stringency conditions is the general principle of all
microarray-based experiments[11].Successfulhybridization
is visualized by labelling of bound target oligonucleotides
withﬂuorescentdyes.Fluorescenceintensityoftherespective
spot on the chips is subsequently used to determine the
presence or absence of a mutation or SNP or the level of
mRNA or miRNA expression in a tissue, respectively [11].
The resulting large data sets on the expression level of up
to ten thousands of genes represent a challenge to the com-
monly used statistic methods. These challenges include the
subtraction of background noise, the normalization of dataThe Scientiﬁc World Journal 3
Table 1: Advantages and limitations of transcriptomics technologies.
qPCR arrays Microarrays Ref-Seq
Advantage Highest sensitivity/speciﬁcity Costume-made assays available
less expensive than Ref-Seq
Combination of quantitative and sequence
information
Limitation Only few hundreds of targets
measurable in parallel Less sensitive and speciﬁc than qPCR Less sensitive and speciﬁc than qPCR
Expansive
to allow for the comparison of diﬀerent microarrays and
microarray experiments with each other, and the identiﬁca-
tion of statistically signiﬁcant changes in large data sets [12].
For the latter, the common statistical test, t-test, ANOVA,
and Mann-Whitney test have been adjusted to consider the
multiple comparisons and permit cluster analysis [13, 14].
However, in most instances, the number of variables is larger
than the observational units. Principal component analysis
andpartialleastsquareshavebeenusedfordimensionreduc-
tion and to visualize microarray data sets [15]. Furthermore,
clustering methods like hierarchical and fuzzy clustering
are used to identify diﬀerences in gene expression proﬁles
associated with diﬀerent disease states or treatment response
[16].
Ready-to-use wholegenomecDNAmicroarraysarecom-
mercially available for several species including human,
mouse, and rat (Aﬀymetrix, Illumina, Agilent) but also for
canine, bovine, porcine, sheep, equine, chicken, rhesus ma-
caque,salmon,andzebraﬁsh (Aﬀymetrix,Agilent).However,
costume-made microarrays with any given DNA of interest
are provided by several local and international suppliers.
These arrays can be adjusted to each experiment in terms of
gene number or type of interest and may therefore represent
a low-cost alternative to expensive full-genome microarrays.
Similar to other analytic tools, microarray experiments
require technical and biological replicates. In addition, sev-
eral initiatives are launched to standardize microarray exper-
iments, whose outcome is strongly inﬂuenced by tissue and
RNA handling, the assay protocols and the microarray plat-
form on the resulting data. For instance, the “minimum
information about a microarray experiment (MIAME)”
and the “microarray quality control (MAQC) project” are
becoming the gold standard of how detailed information on
an experiment should be included in a publication [17, 18].
In summary, microarrays are well established and valu-
able tools to get a ﬁrst impression on the genetic activity or
the genomic composition of a speciﬁc tissue under physi-
ologic and pathologic conditions. Despite the high quality
of prefabricated microarrays, one has to keep in mind that
cross-hybridization and low sensitivity when compared to
quantitative PCR are intrinsic problems of this valuable
methodandmayleadtofalsepositiveornegativeresults[19].
Microarray data can therefore in most circumstances not be
considered as ﬁnal and conclusive information but have to
be conﬁrmed by other methods such as quantitative PCR or,
optimally, on the protein level or by functional cell assays
[17, 18].
2.2.DeepSequencing(RNA-Seq). RNA-Seqisanewapproach
toobtaincompleteinformationontheRNAexpression levels
in a tissue sample [20]. This approach utilizes the tremen-
dous progress in the development of next generation se-
quencing technologies, which allow to sequence millions of
base pairsin arelatively short time[21].Initially, thesemeth-
ods were used for whole-genome sequencing of organisms
[22]o rt u m o u r s[ 23]. Within the past 2-3 years, second-
generation sequencing has been applied to cDNA sequenc-
ing to obtain information on the full set of all tran-
scribed RNA sequences within a given tissue, that is, the
complete transcriptome in so-called RNA-Seq experiments
[24, 25].
R N A - S e qu s e sac D N Al i b r a r y ,w h i c hi sr e v e r s et r a n -
scribed from the total RNA in a single tissue or cell culture
[20]. Small fragments from each of these cDNA molecules
are then sequenced using the diﬀerent technology platforms
Illumina IG[24],AppliedBiosystemsSOLiD[26],Roche454
Life Science [27], or Helicos Biosciences tSMS [28].
Although subsumed under the name “next generation”
or “deep” sequencing, the three main technologies are based
on diﬀerent principles. Pyrosequencing, which has been de-
veloped by 454 Life Sciences, is based on the emulsion
ampliﬁcationofasingle DNAsequenceattached toaprimer-
coated bead, on which a clonal DNA colony is formed in a
picotitre well [29]. The sequencing procedure employs lucif-
erase to generate light for indication of the addition of one
of the four consecutively added dNTP types to the newly
synthesised DNA in each well [29].
In contrast, the reversible dye-terminator-based technol-
ogy of Ilumina employs ampliﬁcation of DNA fragments to
clonalDNAcoloniesonaglassslide.Duringeachsequencing
step,oneofthefourtypesofdNTPisadded,andtheaddition
of the ﬂuorescently labelled nucleotides is detected by a
camera at the respective spot [30]. After each step, the dye
is chemically removed, and the next cycle is started.
The SOLiDtechnologyofAppliedBiosystemsisbased on
sequencing by ligation. Similar to pyrosequencing, DNA is
ampliﬁed by emulsion PCR, and the resulting bead with a
clonal DNA colony is positioned on a glass slide [31, 32].
The mismatch sensitivity of the DNA ligase is then used to
identify the nucleotide present at a given position in a DNA
sequence.
The sequences retrieved from any of these technologies
are aligned to the reference genome, and the resulting infor-
mation can be used to analyze both genomic and posttran-
scriptional mutationsandthemRNAexpression levelofeach
gene. RNA-Seq therefore extends the information obtained
with microarrays by a second dimension, the sequenceof the
mRNA transcripts [20]. This may permit the identiﬁcation
of disease-associated mutations or SNP in the actively tran-
scribed genes [26].4 The Scientiﬁc World Journal
Another advantage of RNA-Seq is potential analysis of
genomes from organisms without complete genomic se-
quence information, although further data analysis in these
cases is oftenhampered by the lack of gene annotation or the
lack of a sequenced genome [33]. This is in strict contrast
to the microarray approach that requires knowledge on the
sequences to be detected [34]. Finally, RNA-Seq also has a
large dynamic range of quantiﬁcation levels which allows the
quantiﬁcation of very low and high quantities in contrast to
thelowsensitivityandreduceddynamicrangeofmicroarrays
[35].
A major disadvantage of this technology is the relatively
high costs for a high coverage analysis of a complex mam-
malian genome [36]. Still, the price per nucleotide is signiﬁ-
cantly lower than for classic sequence; a reasonable RNA-Seq
run requires the analysis of several million bases, making it
still an expansive technology for most scientiﬁc questions.
2.3. Quantitative Real-Time PCR Arrays. Quantitative real-
time PCR (qPCR) arrays are, although less complex, still
a very valuable method for the quantiﬁcation of the gene
expression of up to 600 genes [37]. At the moment, qPCR
a r r a y sa r eac o m m o n l yu s e dm e t h o df o rt h eq u a n t i ﬁ c a t i o n
of the “miRNA transcriptome” [37]. This is mainly based
on two facts. First, the number of miRNA types per species
can be considered at level of hundreds and is therefore much
lower than the number of mRNA types (see http://www.mir-
base.org/,[ 38–40]). Second, the high similarity between the
diﬀerent miRNA types makes the development of microar-
rays diﬃcult due to the high risk of cross-hybridization [41].
In contrast, Taq-Man- or SYBR-Green-based qPCR assays
permit a speciﬁc and sensitive quantiﬁcation of miRNA and
are a commonly used method in veterinary sciences for
the detection of mRNA and miRNA [42–46]. Arranged in
an array, qPCR assays are therefore an eﬃcient and highly
reproducible method to quantify the miRNA transcriptome.
3.MethodsinProteomics
Transcriptome analysis gives useful information on the tran-
scriptional activity of a cell. However, due to posttran-
scriptional gene regulation and the diﬀerent stabilities and
biologicalhalf-lives ofRNAand protein specimens including
miRNA,the correlation betweenmRNA levelsand the corre-
sponding protein is often poor [47]. Transcriptome analysis
therefore requires conﬁrmation of the results on the protein
levelfor most scientiﬁc questions. The analysis ofthe cellular
proteome is, however, a much greater challenge than the
transcriptome duetothe high chemical diversityofthe cellu-
la rpr ot ei n s[48].Despite thesediﬃculties, proteomeanalysis
has become an important tool for explorative analysis of
molecular mechanisms in physiology and pathology [49].
There is a great variety of approaches applied in proteome
research that can be grouped into two broader categories:
gel-based assays and shotgun proteomics (Table 2).
3.1. Gel-Based Proteomics. One of the major problems of
proteomeanalysis is thecomplexityof proteins in tissues and
Table 2: Advantages and limitations of the two major proteomics
approaches.
2D-DIGE Shotgun Proteomics
(MudPit)
Advantage
Moderate costs for
necessary equipment
(separation phase)
Good protein separation
Industrialized work
processes
Almost all protein types
analyzable
Limitation
Gel-based variability
Hydrophobic
(membrane) proteins
diﬃcult to measure
Diﬃcult quantiﬁcation of
low abundance proteins
in complex protein mixes
High costs for equipment
cell lysates. Two-dimensional gel electrophoresis (2D-GE)
which combines two dimensions of physical protein sepa-
ration is a common method to separate proteins by their
chemical properties [50, 51]. In the ﬁrst dimension, the
proteins are separated by their isoelectric point (IP), that is,
they are arranged on a linear gel with an immobilized pH-
gradient according to their content of basic or acidic amino
acids [51, 52]. In the second dimension, IP-separated pro-
teins are separated by their molecular size similar to a con-
ventionalSDS-Page[51, 53]. The orthogonalcombination of
both techniques results in a two-dimensional arrangement
of proteins with a high resolution of single protein types
(Figure 2).
Theseparatedproteinscanbevisualized onthegelbydif-
ferent staining methods, for instance, Compassion brilliant
blue[54],silver (Figure 2)[ 55], or ﬂuorescent stainings [56].
Each of the detected spots onthe acrylamide gel theoretically
consistsofoneproteinspecies,and eachcellorconditionofa
cell is theoretically associated with a speciﬁc pattern of these
spots on the gel. Changes in this spot pattern should there-
fore reﬂect changes of the cellular proteome, for example,
its metabolism and gene activity under diseased or healthy
condition [51].
Two approaches have been developed to compare spot
presence and intensity in 2D-GE gels. In the original single
channel approach, all gels containingone proteinsample, are
stained with same stain and scanned independently [57].
This approach is, however, prone to the technical intergel
variability and has diﬃculties to normalize spot intensity.
The multiplex approach of two-dimensional diﬀerential gel
electrophoresis (2D-DIGE) uses gels which contain up to
three proteinsamples stained with three diﬀerentﬂuorescent
dyes to reduce the gel number [58] .O n eo ft h et h r e es a m p l e s
on each gel usually represents an internal standard, which
allows for normalization of spot intensity between diﬀerent
gels [58].
Detection of the diﬀerences in spot intensity even be-
tween only two gels usually overstrains the human eyes ca-
pacity independent from the method used. Comparison or
quantiﬁcation of spot intensity and presence therefore re-
quires automated digital image analysis [59]. Despite the
high eﬃciency of the available software, comparison of pro-
tein expression patternonpolyacrylamide gelsisstill thema-
jor challenge and weakness of gel-based proteome analysis.The Scientiﬁc World Journal 5
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Figure 2: Gel-based proteomics reduces the complexity, of protein
lysates by two-dimensional separation of proteins, that is, separa-
tion by size and pH. This leads to a high resolution ofsingle protein
which facilitates the quantiﬁcation of their spot size and the ex-
traction of single proteins for subsequent mass spectrometry-based
identiﬁcation of the protein identity.
Evenwith highest accuracy and long experience of the exper-
imenter, preparation of 2D-GE gels without technical arte-
facts is not assured mostly due to random polymerization
artefacts in nonmanufactured gels. Commercially available,
machine-made gels are an interesting but costly alternative
that reduces most of these gel-based artefacts [60].
Once protein spots with a signiﬁcant diﬀerence in inten-
sity between the two disease states are identiﬁed, the protein
type has to be identiﬁed using mass spectrometry. To this
end, the spots with the respective protein are picked and
eluted from the gel and fragmented for mass spectrom-
etry by trypsin-digestion [61]. The molecular weight of
the trypsin digested protein fragments is then determined
using, for instance, Matrix-assisted Laser Desorption/Ioni-
zation (MALDI) [62]. This approach uses trypsin fragment
pattern, the so-called “peptide ﬁngerprint” (PF), to identify
the regulated protein in open source protein databases [63].
WiththisPF,proteindatabasesaresearched todeterminethe
peptide/proteinwiththehighestaccordanceaccordingtosta-
tistical calculations. However, PFs for animal proteomes are
far from being complete, and PFs obtained from proteome
studies in animals are in most cases compared with peptide
masses of human protein in the versatile human data bases.
This may lead to low sequence coverage [64], and peptide
sequencing is required for Mascot MS/MS Ions Search (C.
Weise, Freie Universit¨ at, personal communication).
In summary, gel-based proteomics is still an acceptable
and commonly used approach to analyze the cellular pro-
teome. Its main advantage is the relatively low costs for
equipment when compared to non-gel-based approaches.
Disadvantages are the restriction on hydrophilic proteins
with a pH between 3 and 10, diﬃcult standardization of the
gel preparation, the limited dynamic range, and the limited
sensitivity [65–69].
3.2. Shotgun Proteomics (MudPIT). The term shotgun pro-
teomics is applied due to its similarities with DNA shotgun
sequencing, which sequences multiple short DNA fragments
in complex mixtures and recombines them in silico [48].
Similarly, shotgun proteomics analyses trypsin-digested pro-
tein fragments in complex mixtures by mass spectrometry
after separation by liquid chromatography. This so-called
multidimensional protein identiﬁcation technology (Mud-
PIT) combines at least two chromatography separation steps
with tandem mass spectrometry (Figure 3)[ 70, 71]. The
combination of two chromatographic methods allows for
the separation of digested peptide fragments by at least two
features, for example, charge and hydrophobicity, to reduce
the overall protein complexity [72]. The selection of two
coupled, thus two-dimensional chromatography methods
depends on the scientiﬁc question asked and the experience
of the experimentator. Microcapillaries packed with strong
cation exchange material, reverse phase material, or other
aﬃnity-based chromatographicmaterialaremostcommonly
used. In addition, separation before mass spectrometry may
also include isoelectric focussing and capillary electrophore-
sis which enablesa high resolutionand narrow analytebands
[73].
The diﬀerent peptide fractions are eluted from the chro-
matography columns by alternating salt pulses or organic
mobile gradients. They are subsequently stored or, more
commonly, directly applied to the mass spectrometer [71,
74]. MudPIT approaches commonly use electrospray ion-
ization (ESI) mass spectrometers since the chromatography
eluate can be directly “online” analyzed with a connected ESI
mass spectrometer [75].
Most proteome experiments do not exclusively aim at
identifying the general protein composition in the tissue
lysates but require comparative protein quantiﬁcation. Iso-
topic labelling or label-free methods have been developed
andsuccessfullyappliedinMudPITexperiments[74].Asim-
ple method for label-free quantiﬁcation is the spectral
counting [76]. It uses the observation that the total number
of spectra from a peptide correlates well with the original
abundance of the protein in lysates [77]. However, relative
quantiﬁcation by spectral counting is limited to prefraction-
ated, less complex samples [76], while analysis of complex,
unfractionated samples and low abundant proteins may
result in reduced accuracy [78].
Stable isotope labelling is an alternative strategy to quan-
tify proteinsin MudPITexperiments. Stableisotopelabelling
with amino acids in cell culture (SILAC)is a metabolic label-
ling strategy that has been applied to both cell cultures and
small mammals [79,80].Itrelieson metabolicincorporation
of “light”, native amino acids in one experimental group
or “heavy” amino acids with substituted isotopic deuterium
13C in the other group [80]. A typical experimental design
therefore includes a cell line which is grown in cell culture
mediumwithlightorheavyaminoacidsbutunderotherwise
identical conditions. This leads to the complete replacement
o ft h en a t i v ea m i n oa c i d si nt h e“ h e a v y ”i s o t o p eg r o u pa f t e r
a decent incubation period [81], marking the proteome of
this cell unequivocal. After the intended experiment, this
labelling facilitates the mixture of equal amounts of protein
lysates from both experimental groups and parallel analysis
by mass spectrometry, thus reducing technical artefacts6 The Scientiﬁc World Journal
Complex protein lysate
Identiﬁcation of the separated
proteins by mass spectrometry
1st dimension chromatography
2nd dimension chromatography
6 individual mass spectra
Identiﬁcation of the protein
type by data base search
Figure 3: Shotgun proteomics or MudPIT uses multidimensional chromatographic separation to reduce complexity of protein lysates.
The selection of the type of chromatographic columns depends on the question asked and the technical equipment. The diﬀerent protein
lysate fractions obtained by chromatographic separation ideally contain only one protein type which is subsequently identiﬁed by mass
spectrometric analysis and data base search.
during the spectrometric quantiﬁcation. The diﬀerent iso-
tope mass in the amino acids of the two groups leads to twin
peaks which can be quantiﬁed relatively according to their
intensity ratios [81].
Isotope-coded aﬃnity tags (ICAT) and isobaric tag for
relativeandabsolutequantisation(iTRAQ)relyonthechem-
ical labelling of protein samples after the experiment but
before mass spectrometry [82, 83]. ICAT and iTRAQ assays
label proteins with reactive groups which contain either
heavyorlightisotopes,which allowsthedirectquantiﬁcation
of proteins by mass spectrometry similar to SILAC [82, 83].
In contrast to ICAT and SILAC, the isobaric labelling by
iTRAQdoesnotincreasethecomplexityoftheproteinlysates
and labelling of all peptides in a mixture after the biological
experiment [74]. ICAT and iTRAQ therefore enable the
proteomequantiﬁcationintissuesamplesoflargermammals
which cannot be fed with substituted amino acids only.
In summary, shotgun proteomics analyses the proteome
of complex protein lysates in an industrialized manner with-
out gel-based artefacts. It permits the analysis of a wider
range of proteins includinghydrophobic membrane proteins
and strongly acidic and basic proteins. Limitations are the
restriction of this method to specialized and appropriately
equippedlaboratories and the relatively high costs(Table 2).
4.Questionsto Be Askedin
Transcriptomicsand Proteomics
The “-omics” technologiesenable the parallel analysis ofsev-
eral thousands of biomolecules in a sample instead of the
traditional sequential approach. The comprehensive paral-
lel approach naturally interferes with the sensitivity and
speciﬁcity of detection and quantiﬁcation. However, these
technologies are now on a technological level that facilitates
their application for explorative, descriptive pilot studies
on biological phenomena when the present knowledge is
not suﬃcient to establish a substantiated hypothesis on its
molecular basis. Furthermore, they may also be applied to
overcome deadlocked views and paradigms and to approach
well-known diseases unbiased again.
In the following, three major research ﬁelds are intro-
duced where “-omics” technologies are successfully applied:
biomarker discovery, identiﬁcation of complex, prognostic
gene expression patterns, explorative and hypothesis-driven
proteome, and transcriptome analysis (Figure 4).
4.1. Biomarker Discovery. Ab i o m a r k e rc a nb eD N A ,m R N A ,
miRNA, proteins, or any other biomolecule associated with
a speciﬁc state of the cell or tissue [84]. These markers are
synthesized by the diseased tissue itself or by nondiseased
cells in response to the neoplastic or inﬂammatory disease.
Biomarkers are further subdivided in diagnostic marker
which enablethedetectionofthedisease,prognosticmarkers
which in turn allow for a prediction of the disease course
when the initial diagnosis has been established, and strati-
ﬁcation markers which predict a response to a speciﬁc treat-
ment (reviewed in [84]).
The ideal biomarker therefore permits the diagnosis and
classiﬁcation of a disease with a cheap, sensitive, and speciﬁcThe Scientiﬁc World Journal 7
Biomarker discovery
Which biomolecule indicates
Transcriptomics/proteomics technologies
Prognostic gene
expression patterns
Which set of biomolecules
indicates a poor prognosis/
Explorative analysis
What happens in the cell at all?
the disease in vivo?
a good therapeutic response?
Figure 4: The three main ﬁelds for the application of transcriptomics and proteomics technologies and the basic questions behind these
applications.
assay in a tissue sample which is obtained by a microinva-
sive intervention such as serum samples or small tissue bio-
psies.
Several, well-established biomarkers are used in clinical
biochemistry in daily diagnostic routine. For instance, enzy-
matic activity of alkaline phosphatase (ALP) and other en-
zymes in serum samples are used for the evaluation of the
hepatic function or thyroxin, and sex steroid levels are used
to identify endocrine diseases. Tumor (bio-) markers are a
ﬁeld of speciﬁc interest in the search for biomarkers, and
severalofthemhavebeenintroducedinhumanroutinediag-
nostic,forinstance,alpha-fetoprotein andcarcinoembryonic
antigen [85, 86]. In contrast, several, mostly immunohisto-
chemical but also serum tumor markers have been suggested
in veterinary medicine but are in most cases not routinely
used in the prediction of disease outcome mostly due to low
speciﬁcity and sensitivity (reviewed in [87]).
The complete sequencing of the canine, feline, bovine,
equine, and chicken genome, the availability of manufac-
tured genome microarrays, and the reduction in costs of
transcriptomics and proteomics technology will however
accelerate the search biomarker in veterinary sciences, and
progress in this ﬁled can be expected in the near future
[88–92]. However, biomarker identiﬁcation is, despite the
technological progress, still diﬃcult and requires structured
and expansive analysis and comprehensive evaluation of the
results.
The ﬁrst and in most cases a tremendous hurdle for bio-
marker studies in veterinary medicine is the need for well-
preserved, clinical samples with comprehensive clinical data
on disease outcome. The appropriate number of samples
from a well-deﬁned study population taken with a standard
protocol usually requires multicentred eﬀorts to gain the
criticalmass. Oncea suﬃcientand statisticallyrelevantnum-
ber of clinical samples are available, biomarker discovery is
usually based on a simple comparison of tissue samples from
patients with and without the disease (diagnostic biomark-
ers), certain disease outcomes (prognostic biomarkers), or
diﬀerent responses to therapy (stratiﬁcation biomarkers).
Most biomarker studies are therefore based on the assump-
tionthatspeciﬁcproteinsarepresentinthebloodofapatient
with a particular disease, disease outcome, or reaction to
a drug. However, knowledge on the composition and the
biodynamics of the blood proteome or speciﬁc proteins in
healthy individuals is still far incomplete, and unless these
gaps of knowledge are ﬁlled, important biomarkers may be
possibly missed [93].
Whether proteins, DNA, miRNA, mRNA, or other bio-
molecules are searched as candidates for biomarkers in these
samples depends on the available samples the concurrent
knowledge on disease mechanisms, and the general require-
mentsofthe intendedﬁnal assay. Nonetheless, thereisa clear
trend towards proteomic approaches on easily accessible
body ﬂuids like serum to identify biomarkers for clinical
routinediagnostics.Thisissupportedbythegrowingcontent
of the public protein data bases (SwissProt, UniProt, RCSB)
for human, murine but also other farm and companion
species which facilitates the ﬁrst biomarker discovery studies
in veterinary science.
The work plan for biomarker discovery projects is long
and complicated (reviewed in [93]). Brieﬂy, the early detec-
tion research network (EDRN) has proposed a ﬁve-phase
process for the development and testing of disease biomark-
ers [94].
Explorative preclinical, proteome or transcriptome stud-
ies are proposed as initial ﬁrst phase steps in biomarker
discovery. Which of the “-omics” strategies is utilized is in
most circumstances determined by the available equipment
and the amount of preexisting knowledge of molecular
disease mechanisms (reviewed in [84]). Nevertheless, mass-
spectrometry-based proﬁling by MudPIT proteomics of low
molecular weight proteins (peptidome) in the clinical serum
samples has been given special attention due to the easy
and microinvasive obtainment of such samples in a clinical
environment [95]. In contrast, the cancer biomarker-family
approach is based on the hypotheses that “if a member of
protein family is a biomarker, other members of that family
might also be good biomarkers” [84]. Finally, the secreted-
protein-based approach hypothesizes that a good serological
biomarker should be a secreted protein, and biological
ﬂuids with contact to the tumor site may help in primary
identiﬁcation of these markers [84, 93].
The initial preclinical,explorativephase ofthebiomarker
discovery which includes proteome or transcriptome proﬁl-
ing of the complete set of proteins has to be followed by the
development of clinical assays for the identiﬁed few candi-
dates. The assays are tested retrospective longitudinally and
prospectively to evaluate their sensitivity and speciﬁcity for
disease detection in phases two to four [94]. Finally, in phase
ﬁve, the established assays have to be evaluated in a large8 The Scientiﬁc World Journal
patient population to ensure their clinical eﬃciency and
impact, another phase which requires multicenter collab-
oration to obtain suﬃcient patient numbers [84, 93]. All
of these stages are inﬂuenced by several variables that have
been carefully planed or standardized by standard operating
proceduresbutare beyondthe scope ofthis review(reviewed
in [93]).
Costs areanothercriticalfactorofbiomarkerdiscoveryat
each of the discovery phases. In the initial exploratory phase,
the high costs of modern instrumentations and reagents for
proteomeandtranscriptome analysis arealimiting. Costsfor
commercial proteome analysis are dropping. In the proceed-
ing phases, costs are mainly driven by the development and
validation ofmarker-speciﬁc assays, forexample, ELISA.The
cost for the development of the assays varies but numbers
of 100,000 up to 1,000,000$ have been suggested [96]. In
addition, experience shows that only a small fraction of the
total candidates successfully make good clinical biomarkers
[96]. The high developmental costs for speciﬁc biomarker
detection assays and only to a minor extent the costs for ex-
plorative “-omics” technologies are therefore considered as
the current bottleneck in biomarker discovery [97, 98].
4.2.DetectionofPrognostic GeneExpression Patternsby Super-
vised Gene Expression Proﬁling. Especially in tumor biology,
itbecomes moreandmore evidentthatfor most cancertypes
a malignant phenotype is associated with speciﬁc, complex
changes in gene expression levels and not based on the
expression levels of single genes [99, 100]. This perception
has changed the search for prognostic factors in oncology. In
recent years, expression proﬁling has been used to identify
complex, prognostic gene expression patterns [100–102].
Ideally, gene expression proﬁling focuses on protein expres-
sion levels, since mRNA or miRNA expression levels do not
fully reﬂect the protein expression pattern and the biologic
activity of a cell. However, the technological head start of
mRNAassayslikemicroarraysandnextgenerationsequencer
makes these methods superior to proteome analysis for the
identiﬁcationofprognosticgenesets. Inaddition,prognostic
gene expression patterns do not have to reﬂect the true
biologic state of the cell. Their only function is to diagnose
a disease or predict a disease outcome even if they are based
on biologically irrelevant, phenotypic mRNA patterns.
Two major approaches for gene identiﬁcation are com-
monly used, supervised and unsupervised classiﬁcation
(Figure 5)[ 103].The principleofsupervised geneexpression
proﬁling studies is rather simple [99]. According to the diag-
nostic questions, the completemRNA of tissue samples from
“training” groups of patients with and without the disease or
the intended or not intended therapy outcome are analyzed
to identify genes whose expression level is signiﬁcantly
associated with the respective group [99]. Thus, the tissue
samples are ﬁrst divided by their disease status, and the data
analysis aimsatidentifyingthediﬀerencesinthegeneexpres-
sion proﬁle behind these clinically observed diﬀerences
[99]. In contrast, the unsupervised method diﬀerentiates
tissue samples according to their gene expression proﬁle
without preceding information on their diseases status. This
approach aims at identifying molecular phenotypes within
a by then phenotypically homogeneous disease which may
be of interest for treatment and prognosis. Another method
is to apply experimentally obtained information on gene
expression proﬁles associated with the activation of cer-
tain molecular pathways to classify tumour samples. This
hypothesis-driven gene expression proﬁling approach aims
at diﬀerentiating tumours that depend on these molecular
pathways and may be treated accordingly [99].
T h ed i a g n o s t i cv a l u eo ft h eg e n es e t si d e n t i ﬁ e dw i t h
supervised clustering has to be tested in a second, indepen-
dent “test” group to conﬁrm its usefulness. This group again
consists of a large population of patients with and without
the disease or the diﬀerent therapeutic outcomes. In an
unsupervised approach, the prognostic gene set is now used
to assign tissue samples to one of the groups. According to
the ability to attribute clinical samples to the respective
group, that is, false negative and false positive results, the
speciﬁcity and sensitivity of the gene set are determined.
In 2002, van’t Veer et al. published one of the ﬁrst studies
that identiﬁed a prognostic set of 70 genes for human breast
cancer [100]. In a supervised classiﬁcation approach, they
compared lymph-node-negative breast cancer samples with
short intervals to distant metastases with samples with long
intervals to distant metastasis. By this approach, the authors
identiﬁed a prognostic set of 70 genes that predicts distant
metastases and allows a patient-tailored therapy strategy to
identify patients which beneﬁt from the application of adju-
vant therapy from [100]. Of interest, ﬁrst gene expression
proﬁling studies on canine mammary tumours show that
similar prognostic gene set may exist for malignant canine
mammary tumours although their prognostic relevance has
not been tested in larger patient populations yet (Figure 6)
[101, 102, 104–107]. It can however be assumed that similar
prognostic gene sets will be identiﬁed for veterinary diseases
in the near future, given that aﬀordable molecular tools like
microarrays are now available for the most relevant species
in veterinary science.
Unsupervised cluster analysis and hypothesis-driven
gene expression proﬁling are less successful and promising
strategies to identify prognostic gene expression proﬁles but
may help to understand disease-associated molecular mech-
anisms in explorative and hypothesis-driven transcriptome
and proteome studies.
4.3. Explorative and Hypothesis-Driven Transcriptome and
ProteomeAnalysis. Ideally, scientiﬁc progress is a continuous
hypothesis-driven process by which new ideas are based on
and reﬁne recent ﬁndings. However, occasionally the pre-
existing knowledge is insuﬃcient to establish a substantial
hypothesis. In these cases, transcriptome and proteome
analyses are a promising, explorative approach to obtain
ﬁrst exploitable information on potential molecular disease
mechanisms. Bothsupervisedandunsupervisedgeneexpres-
sion clustering using microarray technology and compara-
tive proteome analysis have been used in veterinary science
to explore the molecular basis of various, mostly neoplastic
diseases [64, 104, 105, 108–110]. All these studies compared
diseased and nondiseased tissues in a supervised approach to
identify genes or molecular pathways with signiﬁcant diseaseThe Scientiﬁc World Journal 9
Unsupervised
classiﬁcation
Clinically similar tissues
Classiﬁcation approaches
Clinically diverse tissues
Supervised
classiﬁcation
Separation according to their molecular
phenotype by transcriptomics tools
Phenotype 1 Phenotype 2
Identiﬁcation of the molecular basis of the
diﬀerent outcomes by transcriptomics tools
Treatment option 1 Treatment option 2 Prognostic and predictive gene set
Disease outcome 1 Disease outcome 2
Figure 5: Two major approaches for the identiﬁcation of disease-relevant gene expression proﬁles are supervised and unsupervised clas-
siﬁcation. Unsupervised classiﬁcation is used to identify diﬀerent molecular mechanisms in tissues from patients with clinically similar
disease phenotypes. Clustering of these tissues according to their molecular phenotype may lead to the identiﬁcation of diﬀerent molecular
phenotypes behindtheidenticalclinicalbehaviour.Thisknowledgemayﬁnallyleadto diversetherapyprotocolsofthesemolecularsubtypes.
In contrast, during supervised clustering, molecular mechanisms behind diﬀerent disease outcome or phenotypes are analyzed. Two tissue
groups with clinical diﬀerences are therefore compared, and the diﬀerences in gene expression are thought to be relevant for the distinct
clinical behaviour. The resulting set of genes may also serve prognostic markers for the prospective classiﬁcation tissue samples.
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Figure 6: First studies in canine mammary tumours show that clinically diﬀerent but histologically similar tumours can be clustered in a
supervised approach into clinically relevant groups by a prognostically relevant gene sets (modiﬁed from [102]).10 The Scientiﬁc World Journal
association. These disease-associated proteins are now to
be tested in further hypothesis-driven experiments to prove
their relevance as primary disease causes or to identify them
as pure phenotypic and secondary eﬀects.
Unsupervised clustering of microarrays data has been
used in human oncology to subclassify histologically identi-
cal cancer samples by their molecular phenotype. This strat-
egy is based on the general hypothesis that a clinically and
morphologically uniform disease may be caused by diﬀerent
molecular mechanisms, that is, that diﬀerent molecular
mechanisms can lead to the same disease or clinical picture.
In one of the ﬁrst studies using this strategy, Perou et al.
investigated the gene expression patterns in breast cancer by
unsupervised hierarchical cluster analysis [111]. They were
able to divide malignant high-grade breast cancer tissue
samples into four diverse subgroups with diﬀerential gene
expression proﬁles. In several ensuing studies, these sub-
groups were reﬁned, and their prognostic and therapeutic
relevance has been conﬁrmed [112]. Similar studies with
impactontheclassiﬁcationofveterinary tumoursarelacking
but hopefully will be available in the near future.
Hypothesis-driven gene expression proﬁling is the com-
plete opposite strategy to unsupervised, explorative gene
expression proﬁling. This strategy uses gene expression sig-
natures which either have been identiﬁed during in vitro or
in vivo experiments using models of the disease of interest
or theoretically by comparison with other diseases, species,
or consideration of known gene functions [99]. The relevant
set of genes or rather “functional” gene expression proﬁles
are applied on preexisting microarray data to subcategorize
the tissues according to the activity of the relevant genes.
For instance, it has been hypothesized that carcinogenesis is
a chronic inﬂammatory process, and a tumor can therefore
be considered as nonhealing wound [99, 113, 114]. Based
on this idea, the gene expression proﬁles of serum-activated
ﬁbroblasts were applied to the gene expression proﬁles of
diﬀerenttumours[113].Ithasbeenshownthatsignaturewas
an independent prognostic factor and showed a strong pre-
diction of metastasis and overall survival and may therefore
represent a hypothesis-based prognostic gene set [115].
Hypothesis-driven gene expression proﬁling studies on
veterinarydiseasesarenotavailablemomentarily,mostprob-
ably to the delayed accumulation of necessary gene expres-
sion data in experimental models. However, due to the
successful application of this approach on human diseases,
it can be expected that similar studies will be available in the
near future.
5.Summary
Transcriptome and proteome analyses have been introduced
as a research tool in most ﬁelds of biomedical research. They
permit the identiﬁcation of prognostically relevant biomark-
ers, gene expression proﬁles, and the understanding of com-
plexmolecularmechanisms incellphysiologyandpathology.
Methods to analyze the transcriptome have made the
greatest advancement so far. cDNA microarrays have been
and are widely used to analyse disease mechanisms and to
identify prognostic gene sets. With the availability of species-
speciﬁc, commercially available and aﬀordable microarrays,
it is expectable that its use is becoming even more relevant
in veterinary science in the next years. However, due to
the intrinsic cross-hybridization and sensitivity issues of the
microarray technology, there are tendencies towards Ref-Seq
or deep sequencing technologies, respectively, as an alterna-
tive method for the analysis of the transcriptome. Ref-Seq
expands transcriptome analysis by the parallel information
on the mutational status of the quantiﬁed mRNA types and
is less dependent on the full genome coverage of a species
in a database. Especially, the latter fact indicates that Ref-
Seq will be helpful in areas of veterinary science with deal
with rather rare species, where microarrays are commercially
not available. A major but most probably temporary disad-
vantage of Ref-Seq is the relatively high costs and the need
of computational power and biostatistical expertise required
to appraise the resulting data masses. The questionable rele-
vance of mRNA expression levels on the biology of a tissue
is, however, a general problem of transcriptome analyses,
independent from the applied technology.
Proteome analysis is therefore considered the ultimate
method for the analysis of disease-associated mechanisms.
Momentarily, the two competing methodical approaches
are 2D-gel electrophoresis-based proteomics and shotgun
proteomics. While 2D-gel electrophoresis allows protein
separation with less expansive equipment and experience,
chromatography-based proteomics seems to be of greater
development potential in terms of mechanisation and stan-
dardization. General hurdles of proteome analyses itself that
still need further development are problems to standardize
the analysis of chemically and biochemically highly diverse
proteins when in tissue lysates, that is, to cover the full
proteome ineach case. Furthermore, there are still sensitivity
issues in mixtures of high-and low-abundance proteins and
the general instability of proteins in tissue samples.
Biomarker discovery is a constantly growing scientiﬁc
ﬁeld which attracted high investments and eﬀorts in the
recent years. Althoughit can bebased onall kindsofbiologic
elements, that is, RNA,metabolites, it is commonly based on
proteome analysis of tissue samples or body ﬂuids. Despite
the initial euphoria, the revenues of the enormous invest-
ments in biomarker discovery are moderate, scientiﬁcally
and commercially. In addition, biomarker discovery in vet-
erinary science is hampered by lack of appropriate tissue
banks with proper clinical data, the high costs for initial
proteome analysis, and the high costs for the establishment
and evaluation of subsequent diagnostic tests.
In terms of data analyses, supervised and unsupervised
clustering analysis are the dominating approaches to identify
disease-associated gene expression. Supervised clustering
allows the identiﬁcation of prognostic gene sets that may
predict disease and treatment outcome and has already been
successfully applied in veterinary science. It is based on the
comparison of gene expression proﬁles of tissue samples
with a known disease outcome. In contrast, unsupervised
clustering is used to elucidate molecular mechanisms behind
morphologically and clinically similar diseases. Application
of this approach on veterinary diseases will certainly reﬁneThe Scientiﬁc World Journal 11
orevenchange ourperception ofmany diseases. Hypothesis-
driven gene expression proﬁling is a less frequently used but
promising approach which experimentally derived expres-
sion proﬁles to identify molecular pathways with relevance
in clinical tissue samples.
In summary, “-omics” technology has made it to a stan-
dard method in human and to a minor extend also in vet-
erinary biomedical research. They are useful tools for the
explorative studies and allow the analysis of complex gene
expression patterns. Given that the costs for these methods
willfurtherdrop,itcanbeexpectedthattheresultsofnumer-
ous transcriptomics and proteomics studies will contribute
totheunderstandingofseveralveterinarydiseasesinthenear
future.
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